These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38906855)

  • 21. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance.
    Baumann C; Ullrich A; Torka R
    Mol Oncol; 2017 Oct; 11(10):1430-1447. PubMed ID: 28675785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
    Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
    Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duodenal mucosa of untreated celiac disease patients has altered expression of the GAS6 and PROS1 and the negative regulator tyrosine kinase TAM receptors subfamily.
    Perez F; Iribarren ML; Olexen CM; Ruera CN; Errasti AE; Guzman L; Garbi L; Carrera Silva EA; Chirdo FG
    Clin Immunol; 2024 Jun; 263():110202. PubMed ID: 38575045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization.
    Cosemans JM; Van Kruchten R; Olieslagers S; Schurgers LJ; Verheyen FK; Munnix IC; Waltenberger J; Angelillo-Scherrer A; Hoylaerts MF; Carmeliet P; Heemskerk JW
    J Thromb Haemost; 2010 Aug; 8(8):1797-808. PubMed ID: 20546121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
    Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
    J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
    Peeters MJW; Rahbech A; Thor Straten P
    Cancer Immunol Immunother; 2020 Feb; 69(2):237-244. PubMed ID: 31664482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
    Ben-Batalla I; Schultze A; Wroblewski M; Erdmann R; Heuser M; Waizenegger JS; Riecken K; Binder M; Schewe D; Sawall S; Witzke V; Cubas-Cordova M; Janning M; Wellbrock J; Fehse B; Hagel C; Krauter J; Ganser A; Lorens JB; Fiedler W; Carmeliet P; Pantel K; Bokemeyer C; Loges S
    Blood; 2013 Oct; 122(14):2443-52. PubMed ID: 23982172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
    Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
    Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyro3/Axl/Mertk-deficient mice develop bone marrow edema which is an early pathological marker in rheumatoid arthritis.
    Waterborg CEJ; Koenders MI; van Lent PLEM; van der Kraan PM; van de Loo FAJ
    PLoS One; 2018; 13(10):e0205902. PubMed ID: 30335822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
    Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
    Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Gas6/TAM in cancer cells and tumor microenvironment.
    Wu G; Ma Z; Cheng Y; Hu W; Deng C; Jiang S; Li T; Chen F; Yang Y
    Mol Cancer; 2018 Jan; 17(1):20. PubMed ID: 29386018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
    Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
    Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
    Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
    Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
    Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Gas6/TAM System and Multiple Sclerosis.
    Bellan M; Pirisi M; Sainaghi PP
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
    Zhu C; Wei Y; Wei X
    Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.